Timothy C Thompson Selected Research

Caveolin 1

1/2020	Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer.
1/2018	Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.
7/2016	Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.
9/2013	Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.
2/2013	Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models.
2/2012	Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.
6/2010	Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes.
5/2010	Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit.
12/2009	Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells.
11/2009	Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Timothy C Thompson Research Topics

Disease

76	Prostatic Neoplasms (Prostate Cancer) 07/2021 - 01/2002
49	Neoplasms (Cancer) 10/2022 - 01/2002
10	Neoplasm Metastasis (Metastasis) 01/2021 - 04/2003
5	Glioma (Gliomas) 04/2014 - 01/2008
4	Disease Progression 01/2020 - 03/2003
3	Adenocarcinoma 01/2021 - 01/2018
3	Prostatic Intraepithelial Neoplasia 02/2012 - 11/2002
3	Margins of Excision 03/2005 - 03/2003
3	Carcinoma (Carcinomatosis) 03/2005 - 03/2003
2	Bites and Stings (Sting) 01/2021 - 11/2020
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 01/2016
2	Infections 04/2007 - 05/2004
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 08/2006 - 09/2003
2	Lung Neoplasms (Lung Cancer) 09/2004 - 05/2002
1	Anorexia 10/2019
1	Neutropenia 10/2019
1	Thrombocytopenia (Thrombopenia) 10/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2019
1	Fatigue 10/2019
1	Dehydration (Water Stress) 10/2019
1	Thrombocytopenia 1 10/2019
1	Thyroid Neoplasms (Thyroid Cancer) 01/2019
1	Hypoxia (Hypoxemia) 01/2018
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2017
1	Ovarian Neoplasms (Ovarian Cancer) 01/2017

Drug/Important Bio-Agent (IBA)

20	Caveolin 1IBA 01/2020 - 10/2002
13	Proteins (Proteins, Gene)FDA Link 04/2014 - 01/2003
12	Biomarkers (Surrogate Marker)IBA 01/2019 - 10/2002
11	AndrogensIBA 01/2021 - 10/2002
8	Prostate-Specific Antigen (Semenogelase)IBA 01/2019 - 11/2002
5	olaparibIBA 01/2021 - 05/2017
5	Biological ProductsIBA 01/2019 - 01/2006
5	Androgen Receptors (Androgen Receptor)IBA 05/2017 - 06/2010
4	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2022 - 05/2014
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2017
4	enzalutamideIBA 11/2019 - 03/2015
4	Pharmaceutical PreparationsIBA 10/2019 - 11/2008
4	AntibodiesIBA 04/2012 - 04/2003
4	Messenger RNA (mRNA)IBA 02/2012 - 05/2002
3	Ganciclovir (Cytovene)FDA LinkGeneric 07/2021 - 04/2006
3	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 01/2002
3	Aurora Kinase AIBA 01/2018 - 06/2013
3	Small Interfering RNA (siRNA)IBA 09/2013 - 12/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2012 - 11/2009
3	ParaffinIBA 03/2005 - 11/2002
2	Thymidine KinaseIBA 07/2021 - 04/2007
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2008
2	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2019
2	AntigensIBA 01/2021 - 05/2015
2	Mitochondrial DNA (mtDNA)IBA 01/2020 - 12/2015
2	LipidsIBA 01/2020 - 07/2016
2	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 11/2019 - 03/2015
2	PlatinumIBA 10/2019 - 01/2017
2	Therapeutic UsesIBA 01/2018 - 02/2014
2	Follistatin-Related ProteinsIBA 01/2018 - 01/2016
2	Hormones (Hormone)IBA 07/2016 - 04/2007
2	Neoplasm Antigens (Tumor Antigens)IBA 05/2015 - 05/2003
2	Androgen Antagonists (Antiandrogens)IBA 03/2015 - 06/2010
2	perifosineIBA 04/2011 - 08/2008
2	Transforming Growth Factor beta1 (TGF beta 1)IBA 11/2009 - 05/2006
2	Proteasome Endopeptidase Complex (Proteasome)IBA 11/2008 - 01/2006
2	Interleukin-12 (IL 12)IBA 05/2004 - 11/2003
1	NAD (NADH)IBA 10/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 10/2022
1	B7-H1 AntigenIBA 01/2021
1	abemaciclibIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	palbociclibIBA 01/2021
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 11/2020
1	InterferonsIBA 11/2020
1	SphingolipidsIBA 01/2020
1	CeramidesIBA 01/2020
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 01/2020
1	GlycosphingolipidsIBA 01/2020
1	SphingomyelinsIBA 01/2020
1	CholesterolIBA 01/2020
1	dinaciclibIBA 11/2019
1	talazoparibIBA 11/2019
1	sofalcone (Solon)IBA 10/2019
1	taxaneIBA 10/2019
1	cabazitaxel FDA Link 10/2019
1	Carboplatin (JM8)FDA LinkGeneric 10/2019
1	Drug CombinationsIBA 10/2019
1	Chemokine ReceptorsIBA 01/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	danusertibIBA 01/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018
1	Testosterone (Sustanon)FDA Link 03/2017
1	3- (carbamoylamino)- 5- (3- fluorophenyl)- N- (3- piperidyl)thiophene- 2- carboxamideIBA 01/2017
1	Docetaxel (Taxotere)FDA Link 06/2015
1	abirateroneIBA 03/2015
1	apalutamideIBA 03/2015

Therapy/Procedure

27	Therapeutics 01/2021 - 10/2002
15	Prostatectomy (Retropubic Prostatectomy) 01/2021 - 11/2002
15	Castration 01/2021 - 09/2009
9	Radiotherapy 01/2021 - 01/2002
3	Drug Therapy (Chemotherapy) 01/2017 - 06/2015
3	Immunotherapy 12/2007 - 01/2003
2	Injections 01/2021 - 05/2003
1	Neoadjuvant Therapy 05/2015